Skip Navigation LinksHome | Newsroom | QIA invests in Ensoma, a genomic medicines company

QIA invests in Ensoma, a genomic medicines company


-The investment will advance innovative gene therapy solutions 

-Leading healthcare funds participated in the investment round

Boston, Doha, 5 January 2023QIA took part in a Series B financing round in Ensoma, a genomic medicines company based in the US. The investment will enable Ensoma to advance the development of its Engenious™ in vivo engineered cell therapy platform and accelerate its pipeline of genomic medicines. 

The Series B financing was co-led by Arix Bioscience and 5AM Ventures, with participation from previous and new investors. In addition to QIA, new investors include Arix Bioscience, Bill & Melinda Gates Foundation Strategic Investment Fund, Solasta Ventures, Catalio Capital Management and Mirae Asset Capital. 
Existing investors in the Series B include 5AM Ventures, F-Prime Capital, Cormorant Asset Management, Viking Global Investors, Takeda Ventures, SymBiosis, Alexandria Venture Investments and Fred Hutchinson Cancer Center.